| Dr Jason Matthew Hanson, MD | |
|
12255 De Paul Dr Ste 830n, Bridgeton, MO 63044-2510 | |
| (314) 291-5307 | |
| (314) 291-0838 |
| Full Name | Dr Jason Matthew Hanson |
|---|---|
| Gender | Male |
| Speciality | Otolaryngology |
| Experience | 32 Years |
| Location | 12255 De Paul Dr Ste 830n, Bridgeton, Missouri |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1063522597 | NPI | - | NPPES |
| 002013172 | Other | MO | PTAN |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Y00000X | Otolaryngology | 103004 (Missouri) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Ssm Depaul Health Center | Bridgeton, MO | Hospital |
| St Lukes Hospital | Chesterfield, MO | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Northwest Otolaryngology Inc | 7416015219 | 3 |
News Archive
The U.S. Department of Health and Human Services' Biomedical Advanced Research and Development Authority (BARDA) awarded a $51 million contract to Emergent BioSolutions, Inc., of Rockville, Md., for the development of a new anthrax vaccine using the protective antigen (rPA) to stimulate a protective immune response that neutralizes the anthrax toxins.
Virginia Commonwealth University and Nostrum Pharmaceuticals, LLC, are pleased to announce the signing of a license agreement for the development of inhaled dapsone for the treatment of respiratory diseases.
Everist Genomics announced today that Executive Vice Chairman Alex Charlton will speak about its breakthrough CardioDefender Device at the Wearable Technologies Conference, January 30, 2012, in Munich.
It is well known that smokers damage their health by directly inhaling cigarette smoke. Now, research published in BioMed Central's open access journal Environmental Health has shown that they are at additional risk from breathing environmental tobacco smoke, contrary to the prevailing assumption that such risks would be negligible in comparison to those incurred by actually smoking.
› Verified 4 days ago
| Entity Name | Mercy Hospitals East Communities |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1851431738 PECOS PAC ID: 1658276811 Enrollment ID: O20031218000107 |
News Archive
The U.S. Department of Health and Human Services' Biomedical Advanced Research and Development Authority (BARDA) awarded a $51 million contract to Emergent BioSolutions, Inc., of Rockville, Md., for the development of a new anthrax vaccine using the protective antigen (rPA) to stimulate a protective immune response that neutralizes the anthrax toxins.
Virginia Commonwealth University and Nostrum Pharmaceuticals, LLC, are pleased to announce the signing of a license agreement for the development of inhaled dapsone for the treatment of respiratory diseases.
Everist Genomics announced today that Executive Vice Chairman Alex Charlton will speak about its breakthrough CardioDefender Device at the Wearable Technologies Conference, January 30, 2012, in Munich.
It is well known that smokers damage their health by directly inhaling cigarette smoke. Now, research published in BioMed Central's open access journal Environmental Health has shown that they are at additional risk from breathing environmental tobacco smoke, contrary to the prevailing assumption that such risks would be negligible in comparison to those incurred by actually smoking.
› Verified 4 days ago
| Entity Name | Northwest Otolaryngology Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1578747408 PECOS PAC ID: 7416015219 Enrollment ID: O20081023000277 |
News Archive
The U.S. Department of Health and Human Services' Biomedical Advanced Research and Development Authority (BARDA) awarded a $51 million contract to Emergent BioSolutions, Inc., of Rockville, Md., for the development of a new anthrax vaccine using the protective antigen (rPA) to stimulate a protective immune response that neutralizes the anthrax toxins.
Virginia Commonwealth University and Nostrum Pharmaceuticals, LLC, are pleased to announce the signing of a license agreement for the development of inhaled dapsone for the treatment of respiratory diseases.
Everist Genomics announced today that Executive Vice Chairman Alex Charlton will speak about its breakthrough CardioDefender Device at the Wearable Technologies Conference, January 30, 2012, in Munich.
It is well known that smokers damage their health by directly inhaling cigarette smoke. Now, research published in BioMed Central's open access journal Environmental Health has shown that they are at additional risk from breathing environmental tobacco smoke, contrary to the prevailing assumption that such risks would be negligible in comparison to those incurred by actually smoking.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Jason Matthew Hanson, MD 12255 De Paul Dr Ste 830n, Bridgeton, MO 63044-2510 Ph: (314) 291-5307 | Dr Jason Matthew Hanson, MD 12255 De Paul Dr Ste 830n, Bridgeton, MO 63044-2510 Ph: (314) 291-5307 |
News Archive
The U.S. Department of Health and Human Services' Biomedical Advanced Research and Development Authority (BARDA) awarded a $51 million contract to Emergent BioSolutions, Inc., of Rockville, Md., for the development of a new anthrax vaccine using the protective antigen (rPA) to stimulate a protective immune response that neutralizes the anthrax toxins.
Virginia Commonwealth University and Nostrum Pharmaceuticals, LLC, are pleased to announce the signing of a license agreement for the development of inhaled dapsone for the treatment of respiratory diseases.
Everist Genomics announced today that Executive Vice Chairman Alex Charlton will speak about its breakthrough CardioDefender Device at the Wearable Technologies Conference, January 30, 2012, in Munich.
It is well known that smokers damage their health by directly inhaling cigarette smoke. Now, research published in BioMed Central's open access journal Environmental Health has shown that they are at additional risk from breathing environmental tobacco smoke, contrary to the prevailing assumption that such risks would be negligible in comparison to those incurred by actually smoking.
› Verified 4 days ago
Dr. Jonathan Jerome Lusardi, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 12255 Depaul Dr 830n, Bridgeton, MO 63044 Phone: 314-291-5307 Fax: 314-291-0838 |